文献速递基础与转化研究临床试验与 GCP

靶向WT1的T细胞受体基因治疗预防急性髓系白血病移植后复发

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.
PubMed 文献 · Nat Med · 2019-06-24

研究从HLA-A2+正常供者中分离高亲和力Wilms瘤抗原1特异性TCR(TCRC4),将其导入EB病毒特异性供者CD8+ T细胞(TTCR-C4)以降低移植物抗宿主病风险并增强输注T细胞存活,在同种异体造血细胞移植后预防性输注给12例患者。输注后中位44个月无复发生存率为100%,而同期88例相似风险AML患者为54%(P=0.002)。TTCR-C4维持TCRC4表达、长期存续并具多能性。

要点

  • TTCR-C4输注后中位44个月无复发生存率100%,同期对照88例为54%(P=0.002)。
  • TTCR-C4维持TCRC4表达、长期存续并具多能性。
  • 该策略似有助于预防移植后高复发风险患者的AML复发。

核心结论

  • 靶向WT1的TCR基因治疗策略似有助于预防移植后高复发风险患者的AML复发。

研究设计与样本

  • 从HLA-A2+正常供者库中分离高亲和力WT1特异性TCR(TCRC4),导入EB病毒特异性供者CD8+ T细胞(TTCR-C4),在同种异体造血细胞移植后预防性输注给12例患者(NCT01640301)。
  • 同期比较组为88例相似风险AML患者。

主要发现

  • 输注后中位44个月无复发生存率为100%,同期比较组88例相似风险AML患者为54%(P=0.002)。
  • TTCR-C4维持TCRC4表达、长期存续并具多能性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapse after allogeneic hematopoietic cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) entering HCT with poor-risk features1-3. When HCT does produce prolonged relapse-free survival, it commonly reflects graft-versus-leukemia effects mediated by donor T cells reactive with antigens on leukemic cells4. As graft T cells have not been selected for leukemia specificity and frequently recognize proteins expressed by many normal host tissues, graft-versus-leukemia effects are often accompanied by morbidity and mortality from graft-versus-host disease5. Thus, AML relapse risk might be more effectively reduced with T cells expressing receptors (TCRs) that target selected AML antigens6. We therefore isolated a high-affinity Wilms' Tumor Antigen 1-specific TCR (TCRC4) from HLA-A2+ normal donor repertoires, inserted TCRC4 into Epstein-Bar virus-specific donor CD8+ T cells (TTCR-C4) to minimize graft-versus-host disease risk and enhance transferred T cell survival7,8, and infused these cells prophylactically post-HCT into 12 patients ( NCT01640301 ). Relapse-free survival was 100% at a median of 44 months following infusion, while a concurrent comparative group of 88 patients with similar risk AML had 54% relapse-free survival (P = 0.002). TTCR-C4 maintained TCRC4 expression, persisted long-term and were polyfunctional. This strategy appears promising for preventing AML recurrence in individuals at increased risk of post-HCT relapse.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Chapuis AG, Egan DN, Bar M, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019. PMID: 31235963. doi:10.1038/s41591-019-0472-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。